{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:03:13Z","timestamp":1793908993711,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T00:00:00Z","timestamp":1534464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1038\/s41416-018-0231-6","type":"journal-article","created":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T11:04:50Z","timestamp":1534331090000},"page":"737-743","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases"],"prefix":"10.1038","volume":"119","author":[{"given":"Quirina C. B. S.","family":"Thio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Alexander","family":"Goudriaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stein J.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno Rui","family":"Paulino Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Sciubba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel P.","family":"Rosovksy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,17]]},"reference":[{"key":"231_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.suronc.2012.04.001","volume":"21","author":"N Eastley","year":"2012","unstructured":"Eastley, N., Newey, M. & Ashford, R. U. Skeletal metastases\u2014the role of the orthopaedic and spinal surgeon. Surg. Oncol. 21, 216\u2013222 (2012).","journal-title":"Surg. Oncol."},{"key":"231_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy, G. R. Metastasis: metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584\u2013593 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"231_CR3","first-page":"87","volume":"4","author":"S Li","year":"2012","unstructured":"Li, S. et al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin. Epidemiol. 4, 87\u201393 (2012).","journal-title":"Clin. Epidemiol."},{"key":"231_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s11999-016-5118-3","volume":"475","author":"QMJ Vliet van der","year":"2016","unstructured":"van der Vliet, Q. M. J. et al. What factors are associated with quality of life, pain interference, anxiety, and depression in patients with metastatic bone disease? Clin. Orthop. Relat. Res. 475, 498\u2013507 (2016).","journal-title":"Clin. Orthop. Relat. Res."},{"key":"231_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3109\/17453679508995508","volume":"66","author":"HC Bauer","year":"1995","unstructured":"Bauer, H. C. & Wedin, R. Survival after surgery for spinal and extremity metastases. Prognostication in 241 patients. Acta Orthop. Scand. 66, 143\u2013146 (1995).","journal-title":"Acta Orthop. Scand."},{"key":"231_CR6","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.1200\/JCO.2005.08.104","volume":"23","author":"SS Nathan","year":"2005","unstructured":"Nathan, S. S. et al. Survival in patients operated on for pathologic fracture: implications for end-of-life orthopedic care. J. Clin. Oncol. 23, 6072\u20136082 (2005).","journal-title":"J. Clin. Oncol."},{"key":"231_CR7","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/cam4.292","volume":"3","author":"H Katagiri","year":"2014","unstructured":"Katagiri, H. et al. New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med. 3, 1359\u20131367 (2014).","journal-title":"Cancer Med."},{"key":"231_CR8","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1007\/s11999-015-4446-z","volume":"473","author":"SJ Janssen","year":"2015","unstructured":"Janssen, S. J. et al. 2015 Marshall Urist Young Investigator Award: prognostication in patients with long bone metastases: does a boosting algorithm improve survival estimates? Clin. Orthop. Relat. Res. 473, 3112\u20133121 (2015).","journal-title":"Clin. Orthop. Relat. Res."},{"key":"231_CR9","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2106\/JBJS.15.00975","volume":"98","author":"NR Paulino Pereira","year":"2016","unstructured":"Paulino Pereira, N. R. et al. Development of a prognostic survival algorithm for patients with metastatic spine disease. J. Bone Jt. Surg. Am. 98, 1767\u20131776 (2016).","journal-title":"J. Bone Jt. Surg. Am."},{"key":"231_CR10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D., & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"231_CR11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436\u2013444 (2008).","journal-title":"Nature"},{"key":"231_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883\u2013899 (2010).","journal-title":"Cell"},{"key":"231_CR13","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl. Cancer Inst. 106, dju124 (2014).","journal-title":"J. Natl. Cancer Inst."},{"key":"231_CR14","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1158\/1055-9965.EPI-14-0146","volume":"23","author":"AJ Templeton","year":"2014","unstructured":"Templeton, A. J. et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol. Biomark. Prev. 23, 1204\u20131212 (2014).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"231_CR15","doi-asserted-by":"publisher","first-page":"e0195042","DOI":"10.1371\/journal.pone.0195042","volume":"13","author":"YA Vano","year":"2018","unstructured":"Vano, Y.-A. et al. Optimal off for neutrophil-to-lymphocyte ratio: fact or fantasy? A prospective cohort study in metastatic cancer patients. PLoS ONE 13, e0195042 (2018).","journal-title":"PLoS ONE"},{"key":"231_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3892\/ol.2011.304","volume":"2","author":"S Wang","year":"2011","unstructured":"Wang, S. et al. The neutrophil\/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis. Oncol. Lett. 2, 735\u2013740 (2011).","journal-title":"Oncol. Lett."},{"key":"231_CR17","first-page":"518","volume":"3","author":"JT Huntington","year":"2013","unstructured":"Huntington, J. T., Butterfield, M., Fisher, J., Torrent, D. & Bloomston, M. The Social Security Death Index (SSDI) most accurately reflects true survival for older oncology patients. Am. J. Cancer Res. 3, 518\u2013522 (2013).","journal-title":"Am. J. Cancer Res."},{"key":"231_CR18","doi-asserted-by":"publisher","first-page":"e51862","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"J Budczies","year":"2012","unstructured":"Budczies, J. et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE 7, e51862 (2012).","journal-title":"PLoS ONE"},{"key":"231_CR19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","volume":"357","author":"F Balkwill","year":"2001","unstructured":"Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539\u2013545 (2001).","journal-title":"Lancet"},{"key":"231_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/BF00402777","volume":"111","author":"Y Shoenfeld","year":"1986","unstructured":"Shoenfeld, Y., Tal, A., Berliner, S. & Pinkhas, J. Leukocytosis in non-hematological malignancies? A possible tumor-associated marker. J. Cancer Res. Clin. Oncol. 111, 54\u201358 (1986).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"231_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"231_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-020712-164023","volume":"9","author":"TN Mayadas","year":"2014","unstructured":"Mayadas, T. N., Cullere, X. & Lowell, C. A. The multifaceted functions of neutrophils. Annu. Rev. Pathol. 9, 181\u2013218 (2014).","journal-title":"Annu. Rev. Pathol."},{"key":"231_CR23","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/jcp.24260","volume":"228","author":"MR Galdiero","year":"2013","unstructured":"Galdiero, M. R., Garlanda, C., Jaillon, S., Marone, G. & Mantovani, A. Tumor associated macrophages and neutrophils in tumor progression. J. Cell. Physiol. 228, 1404\u20131412 (2013).","journal-title":"J. Cell. Physiol."},{"key":"231_CR24","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s10555-015-9594-9","volume":"34","author":"A Swierczak","year":"2015","unstructured":"Swierczak, A., Mouchemore, K. A., Hamilton, J. A. & Anderson, R. L. Neutrophils: important contributors to tumor progression and metastasis. Cancer Metastas. Rev. 34, 735\u2013751 (2015).","journal-title":"Cancer Metastas. Rev."},{"key":"231_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nri1785","volume":"6","author":"C Nathan","year":"2006","unstructured":"Nathan, C. Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 6, 173\u2013182 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"231_CR26","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1242\/jcs.116392","volume":"125","author":"FR Balkwill","year":"2012","unstructured":"Balkwill, F. R., Capasso, M. & Hagemann, T. The tumor microenvironment at a glance. J. Cell Sci. 125, 5591\u20135596 (2012).","journal-title":"J. Cell Sci."},{"key":"231_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/bjc.2011.189","volume":"105","author":"MJM Gooden","year":"2011","unstructured":"Gooden, M. J. M., de Bock, G. H., Leffers, N., Daemen, T. & Nijman, H. W. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br. J. Cancer 105, 93\u2013103 (2011).","journal-title":"Br. J. Cancer"},{"key":"231_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s10120-010-0554-3","volume":"13","author":"H Shimada","year":"2010","unstructured":"Shimada, H. et al. High preoperative neutrophil\u2013lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 13, 170\u2013176 (2010).","journal-title":"Gastric Cancer"},{"key":"231_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s12029-009-9125-4","volume":"41","author":"H Liu","year":"2010","unstructured":"Liu, H. et al. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in rectal carcinoma. J. Gastrointest. Cancer 41, 116\u2013120 (2010).","journal-title":"J. Gastrointest. Cancer"},{"key":"231_CR30","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s12094-012-0872-5","volume":"14","author":"S Cedr\u00e9s","year":"2012","unstructured":"Cedr\u00e9s, S. et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin. Transl. Oncol. 14, 864\u2013869 (2012).","journal-title":"Clin. Transl. Oncol."},{"key":"231_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/bjc.2015.183","volume":"113","author":"CH Koh","year":"2015","unstructured":"Koh, C.-H. et al. Utility of pre-treatment neutrophil\u2013lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br. J. Cancer 113, 150\u2013158 (2015).","journal-title":"Br. J. Cancer"},{"key":"231_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/bjc.2015.200","volume":"113","author":"M Cummings","year":"2015","unstructured":"Cummings, M. et al. Pre-operative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival. Br. J. Cancer 113, 311\u2013320 (2015).","journal-title":"Br. J. Cancer"},{"key":"231_CR33","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00277-013-1978-8","volume":"93","author":"E Kelkitli","year":"2014","unstructured":"Kelkitli, E. et al. Predicting survival for multiple myeloma patients using baseline neutrophil\/lymphocyte ratio. Ann. Hematol. 93, 841\u2013846 (2014).","journal-title":"Ann. Hematol."},{"key":"231_CR34","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s12094-011-0687-9","volume":"13","author":"V Asher","year":"2011","unstructured":"Asher, V., Lee, J., Innamaa, A. & Bali, A. Pre-operative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin. Transl. Oncol. 13, 499\u2013503 (2011).","journal-title":"Clin. Transl. Oncol."},{"key":"231_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-350","volume":"13","author":"S Lee","year":"2013","unstructured":"Lee, S. et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer 13, 350 (2013).","journal-title":"BMC Cancer"},{"key":"231_CR36","doi-asserted-by":"publisher","first-page":"101042831770737","DOI":"10.1177\/1010428317707375","volume":"39","author":"HJ Yang","year":"2017","unstructured":"Yang, H.-J. et al. Pre-operative platelet-to-lymphocyte ratio is a valuable prognostic biomarker in patients with hepatocellular carcinoma undergoing curative liver resection. Tumor Biol. 39, 101042831770737 (2017).","journal-title":"Tumor Biol."},{"key":"231_CR37","first-page":"3229","volume":"37","author":"Y Kitano","year":"2017","unstructured":"Kitano, Y. et al. Effects of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios on survival in patients with extrahepatic cholangiocarcinoma. Anticancer Res. 37, 3229\u20133237 (2017).","journal-title":"Anticancer Res."},{"key":"231_CR38","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ejso.2018.02.209","volume":"44","author":"A Dupr\u00e9","year":"2018","unstructured":"Dupr\u00e9, A. & Malik, H. Z. Inflammation and cancer: what a surgical oncologist should know. Eur. J. Surg. Oncol. 44, 566\u2013570 (2018).","journal-title":"Eur. J. Surg. Oncol."},{"key":"231_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16955-5","volume":"7","author":"RD Dolan","year":"2017","unstructured":"Dolan, R. D., Lim, J., McSorley, S. T., Horgan, P. G. & McMillan, D. C. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis. Sci. Rep. 7, 16717 (2017).","journal-title":"Sci. Rep."},{"key":"231_CR40","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","volume":"91","author":"JJ Caro","year":"2001","unstructured":"Caro, J. J., Salas, M., Ward, A. & Goss, G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91, 2214\u20132221 (2001).","journal-title":"Cancer"},{"key":"231_CR41","doi-asserted-by":"publisher","first-page":"e19956","DOI":"10.1371\/journal.pone.0019956","volume":"6","author":"JA Forsberg","year":"2011","unstructured":"Forsberg, J. A., Eberhardt, J., Boland, P. J., Wedin, R. & Healey, J. H. Estimating survival in patients with operable skeletal metastases: an application of a Bayesian belief network. PLoS ONE 6, e19956 (2011).","journal-title":"PLoS ONE"},{"key":"231_CR42","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ejca.2006.10.014","volume":"43","author":"C Bokemeyer","year":"2007","unstructured":"Bokemeyer, C. et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur. J. Cancer 43, 258\u2013270 (2007).","journal-title":"Eur. J. Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0231-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0231-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0231-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:09Z","timestamp":1684616589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0231-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,17]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["231"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0231-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,17]]},"assertion":[{"value":"29 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. D.M.S. is a consultant for Medtronic, Depuy-Synthes, Stryker, Nuvasive, Baxter. Dr. R.P.R. is a consultant for Bayer and has received funding from Bristol44, Meyer Squibb, Janssen Pharmaceutics, and Daiichi Sankyo. Dr. J.H.S. is a consultant for Medtronic and a speaker for Stryker and AO Spine. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by our Institutional Review Board, the Partners Human Research Committee (PHRC), with a waiver of consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The data that support the findings of this study are available from the corresponding author, Q.C.B.S.T., upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Data availability:"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Note:"}}]}}